Cencora (COR) CFO Eva Boratto Buys 21,304 Shares
On June 29, 2026, Cencora's CFO Eva Boratto bought 21,304 shares of the company's stock, signaling confidence in its future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Eva Boratto, Chief Financial Officer at Cencora, Inc. ($COR), bought 21,304 shares on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $COR is up 6.0% after 1 week, up 13.1% after 1 month and up 21.3% to date (from the $281.10 close on Jun 29, 2026).
COR
Cencora, Inc.
Key Points
- Eva Boratto purchased 21,304 shares of Cencora, Inc. (NYSE: COR) on June 29, 2026, reflecting her commitment to the company's growth.
- Cencora's stock is currently trading around $282.98, well above its 52-week low of $244.82, while analysts maintain a positive outlook.
- The latest analyst consensus suggests a 'Buy' rating with a mean price target of $369.31, indicating optimism about the company's future performance.
Get $COR trade alerts by text
We text you when insiders, Congress or big funds trade $COR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Cencora, Inc. alert may contain errors. Disclosures
CFO Eva Boratto Buys Shares
On June 29, 2026, Eva Boratto, the Chief Financial Officer of Cencora, Inc. (NYSE: COR), bought 21,304 shares of the company's stock. While the exact price of the transaction wasn't disclosed, this purchase comes as the stock trades around $282.98, reflecting Boratto's confidence in the company's future prospects.
Recent Insider Activity
Boratto's recent purchase adds to the interests shown by other insiders. Just earlier, on June 18, 2026, Dermot Mark Durcan bought 4,000 shares of Cencora at an average price of $274.19, totaling about $1,096,760. This consistent buying behavior among insiders may indicate a positive sentiment regarding the company’s direction and performance.
Analysts Set New Price Targets
Cencora has received several analyst ratings recently. On October 16, 2026, UBS maintained a 'Buy' rating with a target price of $400, down from $430. Likewise, on October 7, 2026, Leerink Partners also kept its 'Outperform' rating but raised its target to $388 from $380. RBC Capital reiterated a 'Sector Perform' rating with a target of $330. Overall, analysts remain optimistic about Cencora, reflected in the average target price of $369.31 based on 13 analyst opinions.
Stock Performance Context
Currently, shares of Cencora are trading significantly higher than their 52-week low of $244.82. Compared to a previous close of $308.78, the stock's recent performance suggests some volatility. As it stands, the share price is relatively robust, indicating resilience in a fluctuating market.
What Cencora, Inc. Does
Cencora, Inc. specializes in sourcing and distributing pharmaceuticals both in the U.S. and internationally. The company, formerly known as AmerisourceBergen Corporation, has been operational since 1871 and is headquartered in Conshohocken, Pennsylvania. Cencora's comprehensive services cater to various healthcare providers, enhancing its role in the healthcare supply chain.
What to Watch at Cencora, Inc.
Investors will be looking ahead to Cencora's next earnings report scheduled for November 4, 2026. The recent insider transactions and analyst ratings provide insight into the company's current standing, though the 13F filings reflect positions as of the reporting period and may not represent current holdings. With sustained insider confidence and a supportive analyst outlook, Cencora appears positioned for ongoing interest.
Related Filing Alerts
Source: Eva Boratto's Form 4 filing on $COR (Jun 29, 2026). Find the original filing: COR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts